Monitoring circulating γδ T cells in cancer patients to optimize γδ T cell-based immunotherapy

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Oberg, Hans Heinrich ^a   Kellner, Christian ^a   Peipp, Matthias ^a   Sebens, Susanne ^a   Adam Klages, Sabine ^a   Gramatzki, Martin ^a   Kabelitz, Dieter ^a   Wesch, Daniela ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Aminobisphosphonate; Bispecific antibodies; Human; Monitoring; Pancreatic ductal adenocarcinoma; Phosphorylated antigens; T cells

Indexed keywords

BLINATUMOMAB; CATUMAXOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERTUMAXOMAB; PERTUZUMAB; RITUXIMAB; TRASTUZUMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ADHESION; CELL COUNT; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOGENICITY; PANCREAS ADENOCARCINOMA; TUMOR MICROENVIRONMENT;

EID: 84919479955     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00643     Document Type: Article

References (30)

1. Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, et al. Human ?d T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol (2012) 188:1708-16. doi:10.4049/jimmunol.1102654
2. Meuter S, Eberl M, Moser B. Prolonged antigen survival and cytosolic export in cross-presenting human γδ T cells. Proc Natl Acad Sci U S A (2010) 107:8730-5. doi:10.1073/pnas.1002769107
3. Devilder MC, Allain S, Dousset C, Bonneville M, Scotet E. Early triggering of exclusive IFN-γ responses of human Vγ9Vd2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J Immunol (2009) 183:3625-33. doi:10.4049/jimmunol.0901571
4. Kabelitz D, Kalyan S, Oberg HH, Wesch D. Human Vd2 versus non-Vd2 γδ T cells in antitumor immunity. Oncoimmunology (2013) 2:e23304. doi:10.4161/onci.23304
5. Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, et al. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 10:35-41. doi:10.1038/cmi.2012.39
6. Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH, Minato N, et al. γδ T cells and their potential for immunotherapy. Int J Biol Sci (2014) 10:119-35. doi:10.7150/ijbs.7823
7. Bouet-Toussaint F, Cabillic F, Toutirais O, Le GM, Thomas DLP, Daniel P, et al. Vγ9Vd2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother (2008) 57:531-9. doi:10.1007/s00262-007-0391-3
8. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 67:7450-7. doi:10.1158/0008-5472.CAN-07-0199
9. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother (2007) 56:469-76. doi:10.1007/s00262-006-0199-6
10. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vγ9Vd2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 161:290-7. doi:10.1111/j.1365-2249.2010.04167.x
11. Braza MS, Klein B. Anti-tumour immunotherapy with V?9Vd2 T lymphocytes: from the bench to the bedside. Br J Haematol (2012) 160:123-32. doi:10.1111/bjh.12090
12. Sicard H, Ingoure S, Luciani B, Serraz C, Fournié JJ, Bonneville M, et al. In vivo immunomanipulation of Vγ9 Vd2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol (2005) 175:5471-80. doi:10.4049/jimmunol.175.8.5471
13. Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, et al. Dysfunctional Vγ9Vd2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood (2012) 120:3271-9. doi:10.1182/blood-2012-03-417519
14. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood (2003) 102:200-6. doi:10.1182/blood-2002-12-3665
15. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia (2005) 19:664-70. doi:10.1038/sj.leu.2403693
16. Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, et al. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res (2014) 74:1349-60. doi:10.1158/0008-5472.CAN-13-0675
17. Nicholson JK, Stein D, Mui T, Mack R, Hubbard M, Denny T. Evaluation of a method for counting absolute numbers of cells with a flow cytometer. Clin Diagn Lab Immunol (1997) 4:309-13.
18. Hensley-McBain T, Heit A, De Rosa SC, McElrath MJ, Andersen-Nissen E. Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay. J Vis Exp (2012) 411:23-36. doi:10.3791/4302
19. Sole CV, Calvo FA, Atahualpa F, Berlin A, Herranz R, Gonzalez-Bayon L, et al. Role of radiotherapy in the chemotherapy-containing multidisciplinary management of patients with resected pancreatic adenocarcinoma. Strahlenther Onkol (2014). doi:10.1007/s00066-014-0759-1
20. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell ?d, an autologous cell-therapy product highly enriched in ?9d2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2008) 57:1599-609. doi:10.1007/s00262-008-0491-8
21. Lamb LS Jr, Lopez RD. γδ T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant (2005) 11:161-8. doi:10.1016/j.bbmt.2004.11.015
22. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant (2007) 39:751-7. doi:10.1038/sj.bmt.1705650
23. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells. J Transl Med (2014) 12:45-50. doi:10.1186/1479-5876-12-45
24. Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer (2014) 111:1888-98. doi:10.1038/bjc.2014.388
25. Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematology Am Soc Hematol Educ Program (2013) 2013:584-90. doi:10.1182/asheducation-2013.1.584
26. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, et al. Vγ9 Vd2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int J Cancer (2008) 122:2526-34. doi:10.1002/ijc.23365
27. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther (2012) 136:334-42. doi:10.1016/j.pharmthera.2012.07.013
28. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood (2012) 119:6226-33. doi:10.1182/blood-2012-01-400515
29. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of aß+ T and B cells in children with nonmalignant disorders. Blood (2014) 124:822-6. doi:10.1182/blood-2014-03-563817
30. Drobyski WR, Majewski D, Hanson G. Graft-facilitating doses of ex vivo activated γδ T cells do not cause lethal murine graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 5:222-30. doi:10.1053/bbmt.1999.v5.pm10465102